The Only Approved Drug for His Diagnosis Was Studied in Someone Younger
One approved drug exists for his diagnosis, and the trial that won it enrolled patients up to 55 with active inflammation on their scans. He is 61, ten years in, with two consecutive quiet MRIs. Whether the approval describes him is a different question from whether it covers him.
W.T. retired from the postal service and has spent the last two years as his wife's primary caregiver since her early dementia diagnosis. He is 61. He now needs a cane for any distance past a hundred meters, which in that household is not only a medical fact but a logistical one.
He was diagnosed with primary progressive MS a decade ago, at a point when nothing existed to offer him. Ocrelizumab changed that in 2017 and remains the only disease-modifying therapy approved specifically for PPMS, on the strength of ORATORIO — Montalban and colleagues in the New England Journal of Medicine — which showed a real, statistically significant reduction in twelve-week confirmed disability progression against placebo. By then he and his neurologist had spent six years managing symptoms rather than expecting to slow anything, and had settled into it.
The topline result is not the part that decides his case. ORATORIO's prespecified subgroup analysis concentrated the benefit in younger patients, in shorter disease duration, and in those with gadolinium-enhancing lesions at baseline — markers of inflammation still layered on top of the neurodegeneration that increasingly dominates as PPMS runs on. The trial enrolled ages 18 to 55.
He is 61, ten years past diagnosis, with an EDSS of 5.5 climbed gradually from 3.0 and no enhancing lesion on either of his last two scans. On every axis the subgroup analysis measured, he sits at the far end from the patients who benefited. What he wants to know is not whether the drug works, which the trial answered, but whether it will do anything for someone whose disease no longer looks inflammatory — and he is asking it with a specific reason for needing the answer, since how much longer he can manage his wife's care depends on how fast his own walking goes.
Reviewing whether the trial's benefit applies to him
I'd start ocrelizumab. It remains the only DMT approved specifically for PPMS, and ORATORIO — Montalban and colleagues, New England Journal of Medicine 2017 — showed a real, statistically significant reduction in 12-week confirmed disability progression against placebo. He qualifies for it on label, and withholding the one approved option for a disease that had none for most of his diagnosis needs a stronger reason than subgroup uncertainty.
I've managed PPMS patients through the years when there was genuinely nothing to offer beyond symptom management — that context is doing real work in how I weigh this, and I don't think it should be dismissed as sentiment rather than clinical judgment.
ORATORIO's own prespecified subgroup analysis found the benefit concentrated in younger patients, shorter disease duration, and active gadolinium-enhancing lesions at baseline — and I'd add that the trial enrolled 18 to 55, so he is outside its age range entirely, not merely at its edge. He's sixty-one, ten years in, with no enhancement on his last two scans — the trial's own data points toward the population least likely to see meaningful benefit, not an average case.
I'm not arguing the drug doesn't work at the population level, or that the approval isn't real. I'm saying 'the drug is approved for PPMS' and 'the drug will meaningfully help this specific patient' are two different claims, and the trial's own subgroup data is the reason I don't think they collapse into one here.
I don't think either of you needs to win this on age and disease duration as proxies. Whether his disease still carries any meaningful inflammatory component is a more direct, testable question — a more sensitive MRI protocol and CSF inflammatory markers can look at this more concretely than inferring it from how long ago he was diagnosed.
Both of your positions are reasonable readings of the same trial data, and I'm not resolving which general policy is right — I'm saying we don't have to guess for him specifically when a more direct look at his own disease biology is available before deciding.
Agreed: extended MRI protocol and CSF inflammatory marker panel this visit, with the ocrelizumab decision held until both results return rather than made today on age and disease duration as proxies alone. His physical therapy and mobility-aid plan continues unchanged in the meantime, since neither decision path affects that.
Not agreed: what a genuinely borderline or ambiguous result — some inflammatory marker present, but modestly — should mean for the decision, since neither the Neurologist's nor the MS Neurologist's position was built to resolve a partial finding cleanly. The group named this as a real gap rather than pretending the testing plan would necessarily produce a clean answer.